Atheroma development in apolipoprotein E-null mice is not regulated by phosphorylation of p27Kip1 on threonine 187

Journal of Cellular Biochemistry

Volumn 97, Issue 4, 2006, Pages 735-743

  Sanz Conzález, Silvia M ^a   Melero Fernández De Mera, Raquel ^a   Malek, Nisar P ^b   Andrés, Vicente ^a  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Atherosclerosis; Cell cycle control; p27; Protein phosphorylation; Transgenic animal models

Indexed keywords

APOLIPOPROTEIN E; CYCLIN DEPENDENT KINASE INHIBITOR 1B; THREONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE MUTATION; HYPERCHOLESTEROLEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; RESTENOSIS; TRANSGENIC MOUSE;

ANIMALS; AORTA; APOLIPOPROTEINS E; APOPTOSIS; ATHEROSCLEROSIS; BLISTER; BODY WEIGHT; CELL PROLIFERATION; CHOLESTEROL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIET FADS; FEMALE; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHORYLATION; THREONINE;

ANIMALIA; MAMMALIA; MUS MUSCULUS;

EID: 33645007053     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20680     Document Type: Article

References (57)

1. Andrés V. 2004. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: New perspectives and therapeutic potential. Cardiovasc Res 63:11-21.
2. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, Nabel EG. 2002. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J 21:3390-3401.
3. Boehm M, Olive M, True AL, Crook MF, San H, Qu X, Nabel EG. 2004. Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism. J Clin Invest 114:419-426.
4. Kip1 in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J Clin Invest 104:815-823.
5. Burke-Gaffney A, Brooks AV, Bogle RG. 2002. Regulation of chemokine expression in atherosclerosis. Vascul Pharmacol 38:283-292.
6. Carrano AC, Eytan E, Hershko A, Pagano M. 1999. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Natl Cell Biol 1:193-199.
7. Kip1 in smooth muscle cells from different vascular beds. A potential role in establishing regional phenotypic variance. J Biol Chem 278:4482-4490.
8. Chen D, Krasinski K, Sylvester A, Chen J, Nisen PD, Andres V. 1997. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J Clin Invest 99:2334-2341.
9. kip1. Natl Med 6:1235-1240.
10. Chopra S, Fernandez De Mattos S, Lam EW, Mann DJ. 2002. Jab1 co-activation of c-Jun is abrogated by the serine 10-phosphorylated form of p27Kip1. J Biol Chem 277:32413-32416.
11. Connor MK, Kotchetkov R, Cariou S, Resch A, Lupetti R, Beniston RG, Melchior F, Hengst L, Slingerland JM. 2003. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 14:201-213.
12. Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. 2004. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase. J Biol Chem 279:22498-22504.
13. Díez-Juan A, Andrés V. 2001. The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis. FASEB J 15:1989-1995.
14. Díez-Juan A, Andrés V. 2003. Coordinate control of proliferation and migration by the p27Kip1/cyclin-dependent kinase/ retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. Circ Res 92:402-410.
15. Díez-Juan A, Pérez P, Aracil M, Sancho D, Bernad A, Sánchez-Madrid F, Andrés V. 2004. Selective inactivation of p27(Kip1) in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. Blood 103:158-161.
16. Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S. 2001. Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 276:48937-48943.
17. Hengst L, Reed SI. 1996. Translational control of p27Kip1 accumulation during the cell cycle. Science 271:1861-1864.
18. Ho MK, Springer TA. 1983. Tissue distribution, structural characterization, and biosynthesis of Mac-3, a macrophage surface glycoprotein exhibiting molecular weight heterogeneity. J Biol Chem 258:636-642.
19. Hurteau JA, Brutkiewicz SA, Wang Q, Allison BM, Goebl MG, Harrington MA. 2002. Overexpression of a stabilized mutant form of the cyclin-dependent kinase inhibitor p27(Kip1) inhibits cell growth. Gynecol Oncol 86:19-23.
20. Kip1 and cyclin E in human atherosclerotic tissue: Implications for lesion cellularity. Atherosclerosis 144:7-14.
21. Ishida N, Kitagawa M, Hatakeyama S, Nakayama K. 2000. Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability. J Biol Chem 275:25146-25154.
22. Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI. 2002. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 277:14355-14358.
23. Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, Yoshida M, Nakayama K, Nakayama KI. 2004. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Natl Cell Biol 6:1229-1235.
24. Kossatz U, Dietrich N, Zender L, Buer J, Manns MP, Malek NP. 2004. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev 18:2602-2607.
25. Kotake Y, Nakayama K, Ishida N, Nakayama KI. 2004. Role of serine-10 phosphorylation in p27 stabilization revealed by analysis of p27 knock-in mice harboring a serine-10 mutation. J Biol Chem 280:1095-1102.
26. Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868-874.
27. Libby P, Sukhova G, Lee RT, Galis ZS. 1995. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 25 (Suppl 2):S9-S12.
28. KIP1 inhibitor characterize early development of promyeloid cells into macrophages. Mol Cell Biol 19:6229-6239.
29. Lusis AJ. 2000. Atherosclerosis. Nature 407:233-241.
30. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM, Kyriakidis TR. 2001. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 413:323-327.
31. Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, Koff A. 1997. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 272:7093-7098.
32. Miskimins WK, Wang G, Hawkinson M, Miskimins R. 2001. Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Mol Cell Biol 21:4960-4967.
33. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. 1999. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13:1181-1189.
34. Morgan DO. 1995. Principles of CDK regulation. Nature 374:131-134.
35. Morisaki H, Fujimoto A, Ando A, Nagata Y, Ikeda K, Nakanishi M. 1997. Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (Cdk) inhibitor by cyclin E/Cdk2. Biochem Biophys Res Commun 240:386-390.
36. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, Kitagawa M, Hatakeyama S. 2000. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 19:2069-2081.
37. Olson NE, Kozlowski J, Reidy MA. 2000. Proliferation of intimal smooth muscle cells. Attenuation of basic fibroblast growth factor 2-stimulated proliferation is associated with increased expression of cell cycle inhibitors. J Biol Chem 275:11270-11277.
38. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
39. Park KH, Seol JY, Kim TY, Yoo CG, Kim YW, Han SK, Shim YS, Lee CT. 2001. An adenovirus expressing mutant p27 showed more potent antitumor effects than adenovirus-p27 wild type. Cancer Res 61:6163-6169.
40. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-353.
41. Ross R. 1999. Atherosclerosis: An inflammatory disease. N Engl J Med 340:115-126.
42. Servant MJ, Coulombe P, Turgeon B, Meloche S. 2000. Differential regulation of p27(Kip1) expression by mitogenic and hypertrophic factors: Involvement of transcriptional and posttranscriptional mechanisms. J Cell Biol 148:543-556.
43. Sherr CJ, Roberts JM. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512.
44. Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, Reed SI. 2001. A CDK-independent function of mammalian Cks1: Targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell 7:639-650.
45. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W. 1999. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Natl Cell Biol 1:207-214.
46. Sylvester AM, Chen D, Krasinski K, Andrés V. 1998. Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation. J Clin Invest 101:940-948.
47. Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL. 2004. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 104:11-18.
48. Tanner FC, Yang Z-Y, Duckers E, Gordon D, Nabel GJ, Nabel EG. 1998. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res 82:396-403.
49. Ink4 on vascular smooth muscle cell proliferation. Circulation 101:2022-2025.
50. Tomoda K, Kubota Y, Kato J. 1999. Degradation of the cyclin-dependent- kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398:160-165.
51. Tomoda K, Kubota Y, Arata Y, Mori S, Maeda M, Tanaka T, Yoshida M, Yoneda-Kato N, Kato JY. 2002. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J Biol Chem 277:2302-2310.
52. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. 1999. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9:661-664.
53. Vidal A, Koff A. 2000. Cell-cycle inhibitors: Three families united by a common cause. Gene 247:1-15.
54. Vlach J, Hennecke S, Amati B. 1997. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16:5334-5344.
55. Walsh K, Isner JM. 2000. Apoptosis in inflammatory-fibroproliferative disorders of the vessel wall. Cardiovasc Res 45:756-765.
56. Yang Z, Oemar BS, Carrel T, Kipfer B, Julmy F, Lüscher TF. 1998. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: Role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation 97:181-187.
57. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468-471.